PHASE Scientific, a fast-growing biotechnology company, announces today it has received approval from India’s Central Drugs Standard Control Organization (CDSCO) for its PHASIFY™ VIRAL RNA Extraction Kit. This approval confirms that PHASIFY™ VIRAL complies with the provisions of India’s Medical Devices Rules, 2017, which enables PHASE Scientific to expand commercialization of PHASIFY™ VIRAL to India as part of the fight against COVID-19.

 

The CE-marked PHASIFY™ VIRAL RNA Extraction Kit is designed to purify and concentrate viral RNA in patient viral transport media samples, and is intended to help detecting and controlling the COVID-19 disease in India, which is currently the country with the 3rd-most COVID-19 infections. PHASIFY™ VIRAL improves input sample quality, enabling earlier detection, improved overall sensitivity and bolsters confidence in COVID-19 diagnostic test results.

 

PHASE Scientific has developed an array of products to combat COVID-19, which includes antibody rapid tests, sample preparation kits, and RT-qPCR kits. PHASE Scientific is currently providing their products globally to over 20 countries and regions.

 

Learn more about PHASIFY VIRAL at www.phasescientific.com/product/phasify-viral/

For product inquiries (India), please contact meridianbiotech3@gmail.com

For media and investor relations, contact us at info@phasesci.com

 

 


 

About PHASE Scientific

 

PHASE Scientific is a high-growth biotech company founded by bioengineers from UCLA. We build tools that empower people by giving them better information about their health. Now headquartered in Hong Kong, our global footprint includes R&D and manufacturing facilities in Southern California and offices in Mainland China.